Recombinant Human Erythropoietin

Recombinant Human Erythropoietin Injection

Presentation :Epomax 5000 Injection : Each 0.5 ml Pre-filled Syringe contains Erythropoietin concentrated solution (rDNA) BP 5000 IU

Indications: Erythropoietin is indicated for the treatment of 1.Anemia associated with Chronic Renal Failure, including patients on dialysis (ESRD) and patients not on dialysis.2.Anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. 3. Anemic patients (hemoglobin > 10 to < 13>4. Anemia related to therapy with zidovudine in HIV-infected patients.


Treatment of anemia In chronic renal failure: Erythropoietin is administered to maintain hemoglobin concentration between 11 to 12 g/dl and hematocrit of 33 - 36 % in adults.

Starting dose: Adult: usually 50 to 100 IU/kg three times in a week (TIW) by IV or Subcutaneous route Pediatric: 50 IU/kg TIW by IV or Subcutaneous route

Dose adjustment: Dose should be increased if hematocrit doses not increase by 5 to 6 points after 8 weeks therapy, and hematocrit is below suggested target range. Dose should be reduced when hematocrit approaches 36% or hematocrit increases > 4 points in any 2-week period.

Treatment of anemia in cancer patients on chemotherapy Starting dose: Adult: 150 IU/kg TlW by Subcutaneous route or 40,000 IU Subcutaneous route weekly Pediatric: 25 to 300 IU/kg 3 to 7 times per week by Subcutaneous or IV route.

Packing Epomax-5000 IU: Each box contains 1 pre-filied syringe containing 5000 IU of recombinant Erythropoietin.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.